BioAffinity Technologies Change in Accounts Payable 2022-2025 | BIAF

BioAffinity Technologies change in accounts payable from 2022 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

BioAffinity Technologies Change in Accounts Payable 2022-2025 | BIAF

BioAffinity Technologies change in accounts payable from 2022 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.3B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$118.7B
Bristol Myers Squibb (BMY)$90B
CSL (CSLLY)$82.4B
GSK (GSK)$76.7B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$52.4B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$25.8B
Royalty Pharma (RPRX)$20.9B
Insmed (INSM)$20.6B
Biogen (BIIB)$19.3B
Illumina (ILMN)$15B
Incyte (INCY)$14.8B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$11.1B
Moderna (MRNA)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Halozyme Therapeutics (HALO)$7.3B